Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism
作者:Hiroshi Miyazaki、Yousuke Ikeda、Osamu Sakurai、Tsutomu Miyake、Rie Tsubota、Jyunko Okabe、Masataka Kuroda、Yutaka Hisada、Tetsuya Yanagida、Hikaru Yoneda、Yukihito Tsukumo、Shin Tokunaga、Takehisa Kawata、Rikiya Ohashi、Hajime Fukuda、Koki Kojima、Ayako Kannami、Takayuki Kifuji、Naoya Sato、Akiko Idei、Taku Iguchi、Tetsuya Sakairi、Yasunori Moritani
DOI:10.1016/j.bmcl.2018.04.055
日期:2018.6
The calcium-sensing receptor (CaSR) plays an important role in sensing extracellular calcium ions and regulating parathyroid hormone secretion by parathyroid gland cells, and the receptor is a suitable target for the treatment of hyperparathyroidism. Cinacalcet hydrochloride is a representative CaSR agonist which widely used for the hyperparathyroidism. However, it has several issues to clinical use
钙敏感受体(CaSR)在检测细胞外钙离子和调节甲状旁腺细胞分泌的甲状旁腺激素中起重要作用,并且该受体是治疗甲状旁腺功能亢进症的合适靶标。盐酸西那卡塞是一种代表性的CaSR激动剂,广泛用于甲状旁腺功能亢进症。但是,它对临床使用存在一些问题,例如恶心/呕吐和对CYP2D6的强抑制作用。我们试图改善cinacalcet的这些问题,从而使新药物成为可取的CaSR激动剂。通过cinacalcet的优化可鉴定出吡咯烷化合物,并成功地导致了evocalcet作为口服变构CaSR激动剂的发现。Evocalcet具有高度有利的特性,例如CaSR激动活性和良好的DMPK特性,